Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04044339 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT04044339 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 56 participants.
The verdict
NCT04044339, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy subjects and Part B is a multiple ascending dose (MAD) study in healthy subjects.
Interventions
- DRUG Placebo
- DRUG TD-5202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-08-08 |
| Est. Completion | 2019-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04044339
The ClinicalTrials.gov registry entry for NCT04044339 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04044339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04044339 about?
NCT04044339 is a clinical study titled "Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects". This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy subjects and Part B is a multiple ascending dose (MAD) study in healthy subjects.
What is the current status of trial NCT04044339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-08-08. Estimated completion is 2019-11-27.
What interventions are being tested in trial NCT04044339?
The interventions under investigation include: Placebo (DRUG), TD-5202 (DRUG).
Who is sponsoring clinical trial NCT04044339?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.